NorthWest Biotherapeutics Inc (NWBO)

[jondoeuk]

Other current blockbuster immunotherapy treatments including tecentric, and the Keytrudas/CarT treatments were yielding 15-22% type responses and less than 10% complete responses

Looking at certain CAR-T's, the ORR from the ZUMA-1 trial (R/R NHL) was 82%, with a CR rate of 54%. Moving to ZUMA-7 (second-line LBCL), the ORR was 83%, with a CR rate of 65%. Finally, ZUMA-12 (first-line LBCL), the ORR was 89%, with a CR rate of 78%.